Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
- PMID: 28585089
- DOI: 10.1007/s11010-017-3084-z
Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
Abstract
Glucocorticoid, such as dexamethasone (Dex) is often used along with chemotherapy to antagonize side effects of chemotherapy. However, sustained use of Dex frequently develops drug resistance in patients. As a strategy to re-induce drug sensitivity, we planned to modify Dex by chemically conjugating it with twin ten carbon aliphatic chain containing cationic lipid. The resultant molecule, DX10, inhibited STAT3 activation through lowering the production of IL-6. To enhance the STAT3 inhibitory effect of DX10, we used WP (a commercially available STAT3 inhibitor) along with DX10. Combination treatment of both significantly inhibited STAT3 activation when compared to either of the individual treatment. The effect of DX10, either in combination or alone, was mediated through glucocorticoid receptor (GR), thereby repurposing the role of GR in the context of p-STAT3 inhibition-mediated cancer treatment. Cellular viability study proved the synergistic effect of WP and DX10. Further, combination treatment led to induction of early stage of apoptosis and cell cycle arrest. In vivo melanoma tumor regression study confirmed the enhanced anti-tumor activity of co-treatment over individual treatment of DX10 or WP. Thus, together our result demonstrates that DX10 may be used in combination therapy with STAT3 inhibitor like WP for combating cancer with constitutively active STAT3.
Keywords: Dexamethasone derivative; Drug sensitization; Glucocorticoid receptor; Repurposing WP1066; STAT3 inhibition.
Similar articles
-
Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.Genet Mol Res. 2015 Mar 30;14(1):2450-60. doi: 10.4238/2015.March.30.3. Genet Mol Res. 2015. PMID: 25867391
-
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.Int J Cancer. 2012 Jul 1;131(1):8-17. doi: 10.1002/ijc.26307. Epub 2011 Aug 24. Int J Cancer. 2012. PMID: 21792892 Free PMC article.
-
A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.Cancer Immunol Immunother. 2009 Jul;58(7):1023-32. doi: 10.1007/s00262-008-0618-y. Epub 2008 Nov 11. Cancer Immunol Immunother. 2009. PMID: 19002459 Free PMC article.
-
The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells.Biochem Biophys Res Commun. 2015 Aug 14;464(1):292-8. doi: 10.1016/j.bbrc.2015.06.145. Epub 2015 Jun 24. Biochem Biophys Res Commun. 2015. PMID: 26116769
-
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.Neoplasia. 2015 Jul;17(7):564-73. doi: 10.1016/j.neo.2015.07.003. Neoplasia. 2015. PMID: 26297434 Free PMC article.
Cited by
-
Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement.ACS Omega. 2024 Aug 28;9(36):37901-37909. doi: 10.1021/acsomega.4c00710. eCollection 2024 Sep 10. ACS Omega. 2024. PMID: 39281932 Free PMC article.
-
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges.Transl Breast Cancer Res. 2023 Apr 30;4:16. doi: 10.21037/tbcr-23-17. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751461 Free PMC article. Review.
-
Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.Cancers (Basel). 2024 Jan 24;16(3):492. doi: 10.3390/cancers16030492. Cancers (Basel). 2024. PMID: 38339245 Free PMC article. Review.
-
Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.Front Cell Dev Biol. 2023 Apr 26;11:1183328. doi: 10.3389/fcell.2023.1183328. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37181747 Free PMC article. Review.
-
STAT3 pathway in cancers: Past, present, and future.MedComm (2020). 2022 Mar 23;3(2):e124. doi: 10.1002/mco2.124. eCollection 2022 Jun. MedComm (2020). 2022. PMID: 35356799 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous